NCT06165822 - A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

March 31, 2024

Conditions

Advanced Malignant Neoplasm

Interventions

DRUG

TQB3909 tablets

TQB3909 100mg/tablet.

DRUG

Itraconazole capsule

Itraconazole capsule is a strong inhibitor of CYP3A4.

DRUG

Rifampicin capsule

Rifampicin capsule is a strong inducer of CYP3A4.

Trial Locations (1)

The First People's Hospital of Changzhou, Changzhou